Myositis-specific autoantibodies are specific for myositis compared to genetic muscle disease
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received June 26, 2015
- Accepted in final form September 16, 2015
- First Published November 19, 2015.
Author Disclosures
- Andrew L. Mammen, MD, PhD,
- Livia Casciola-Rosen, PhD,
- Lisa Christopher-Stine, MD, MPH,
- Thomas E. Lloyd, MD, PhD and
- Kathryn R. Wagner, MD, PhD
- Andrew L. Mammen, MD, PhD,
aTYR pharmaceuticals advisory board Biogen advisory board
NONE
NONE
Experimental Neurology, Editorial Board, 2013-Arthritis and Rheumatism, Editorial Board, 2014-
Patented test for anti-HMGCR antibodies that is licensed to INOVA diagnostics
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NIH, K08
NONE
NONE
NONE
Licensed test for anti-HMGCR antibodies to INOVA Diagnostics
Licensed test for anti-HMGCR antibodies to INOVA Diagnostics
NONE
NONE
NONE
- Livia Casciola-Rosen, PhD,
NONE
NONE
NONE
NONE
HMGCR antibody assay
NONE
NONE
NONE
NONE
NONE
NONE
NONE
R56-A062615 (NIH bridge award- NIAMS)
RO1-AR-44684 (NIH grant - NIAMS)
Jerome L Greene Foundation
NONE
NONE
HMGCR antibody ELISA assays (INOVA Diagnostics)
NONE
NONE
NONE
- Lisa Christopher-Stine, MD, MPH,
(1)Novartis (2) Medimmune (3) Walgreen's/Optioncare (40 Mallinckrodt (40 Idera Pharmaceuticals(
NONE
Inova diagnostics
NONE
(1) Detection of HMGCoA reductase (HMGCR) Antibodies in Patient Sera
NONE
NONE
(1) Mallinckrodt Pharamaceuticals (2) Astellas (3) Ono Pharma UK (4) Marathon Pharmaceuticals
NONE
NONE
NONE
(1) NuFactor (2) Walgreens (3) IgG America (4) MedProRx
1) NHLBI ?Inflammation and Coronary Endothelial Function (HL120905) DSMB Chair (2) NHLBI ?Inflammatory pathogenesis of coronary atherosclerosis in HIV (HL14023).?
NONE
Donald B. and Dorothy L. Stabler Foundation
NONE
NONE
(1) Detection of HMGCoA reductase (HMGCR) Antibodies in Patient Sera, Royalties, 2012
NONE
NONE
(1) McAloon and Friedman, P.C. 2014,2015 (2) Shaub, Ahmuty, Citrin, and Spratt, LLP 2014 (expert witness) (3) The Chartwell Law Offices, LLP (expert witness0
- Thomas E. Lloyd, MD, PhD and
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
08/01/2013 -11/30/2016 Sponsor: Novartis Study of efficacy and safety of BYM338 in sporadic inclusion body myositis Role: Site PI, 10% effort
04/15/2013-03/31/2018 NIH/NINDS RO1 NS082563 role: PI, 50% effort
NONE
08/01/2013 ? 07/31/2016 MDA Award 277551 Muscular Dystrophy Association PI: Charlotte Sumner, M.D., Role: Co-PI, 0% effort 08/15-07/17 Axonal transport and retrograde signaling in Drosophila models of c9-ALS Sponsor: Robert Packard Center for ALS Research Role: PI, 0% effort 08/14-07/15 Role of Nuclear Transport Defects in the Pathogenesis of ALS/FTD Sponsor: ALSA $80,000 per year Role: PI, 10%
NONE
NONE
NONE
NONE
NONE
NONE
- Kathryn R. Wagner, MD, PhD
SAB of SOLID GT, FSH Society, PPMD DSMB of CINRG
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NICHD, NCATS
NONE
Team Saij
NONE
NONE
NONE
NONE
NONE
NONE
- From the National Institute of Arthritis and Musculoskeletal and Skin Diseases (A.L.M.), NIH, Bethesda; the Departments of Neurology (A.L.M., L.C.-S., T.E.L., K.R.W.), Medicine (L.C.-R., L.C.-S.), and Neuroscience (T.E.L., K.R.W.), Johns Hopkins University School of Medicine, Baltimore; and The Hugo W. Moser Research Institute (K.R.W.), Kennedy Krieger, Baltimore, MD.
- Correspondence to Dr. Mammen: andrew.mammen{at}nih.gov
Article usage
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Babak Hooshmand and Dr. David Smith
► Watch
Related Articles
- No related articles found.
Topics Discussed
Alert Me
Recommended articles
-
Article
Identification of distinctive interferon gene signatures in different types of myositisIago Pinal-Fernandez, Maria Casal-Dominguez, Assia Derfoul et al.Neurology, August 21, 2019 -
Article
More prominent muscle involvement in patients with dermatomyositis with anti-Mi2 autoantibodiesIago Pinal-Fernandez, Christopher A. Mecoli, Maria Casal-Dominguez et al.Neurology, October 08, 2019 -
Article
Muscular and extramuscular features of myositis patients with anti-U1-RNP autoantibodiesMaria Casal-Dominguez, Iago Pinal-Fernandez, Andrea M. Corse et al.Neurology, March 01, 2019 -
Article
Muscular and extramuscular clinical features of patients with anti-PM/Scl autoantibodiesRebecca De Lorenzo, Iago Pinal-Fernandez, Wilson Huang et al.Neurology, May 04, 2018